Western Securities·2025-08-13 01:20Group 1: Guanggang Gas (688548.SH) - The company's Q2 2025 profitability has rebounded sequentially, with revenue of 5.66 billion yuan, a year-on-year increase of 10.60% and a quarter-on-quarter increase of 3.24% [6] - The company reported a H1 2025 revenue of 11.14 billion yuan, a year-on-year increase of 14.56%, but a net profit of 1.03 billion yuan, a year-on-year decrease of 21.14% [6][7] - The company is expected to achieve net profits of 256 million, 410 million, and 589 million yuan for 2025-2027, corresponding to PE ratios of 52.4, 32.7, and 22.7 times, respectively [8] Group 2: Hutchison China MediTech (0013.HK) - The company reported H1 2025 revenue of 277.7 million USD, a decrease of 9%, with the oncology/immunology business declining by 15% [10][11] - The updated revenue forecast for 2025-2027 is 605 million, 652 million, and 721 million USD, with year-on-year growth rates of -4.0%, 7.7%, and 10.7% [12] - The company has a strong cash position of 1.3645 billion USD, which supports the development of its ATTC platform, expected to contribute to revenue growth [12] Group 3: Boyuan Chemical (000683.SZ) - The company reported H1 2025 revenue of 5.916 billion yuan, a year-on-year decrease of 16.31%, and a net profit of 743 million yuan, a decrease of 38.57% [14][15] - The company expects net profits of 1.48 billion, 2.006 billion, and 2.33 billion yuan for 2025-2027, with corresponding PE ratios of 14.6, 10.7, and 9.3 times [16] - The Alashan natural soda project is progressing, with plans for completion by the end of 2025, which is expected to enhance production capacity [16]